Literature DB >> 333792

Malignant glial neoplasms: definition of a humoral host response to tumor-associated antigen(s).

K M Sheikh, M L Apuzzo, K R Kochsiek, M H Weiss.   

Abstract

There is increasing evidence that human tumors possess tumor-associated neo-antigens. The host mounts an immunological response to these antigens, as evidenced by the detection of circulating humoral antibodies in a variety of human neoplasia.An indirect immunofluorescent antibody technique was employed to detect antibodies to tumor-associated antigens in the sera of patients with malignant gliomas. Viable single cell suspensions were used to demonstrate antibodies to surface contents of tumor cells and cell preparations were snap-frozen at -160° C to demonstrate antibodies to cytoplasmic components of tumor cells. After incubation with serum, the preparations were treated with polyvalent sheep antihuman globulin conjugated to isomer-1-fluorescein isothiocyanate, washed, and examined with a Leitz incident fluorescent microscope.Of the 17 sera from histologically proven malignant glial neoplasm patients, 2 (11%) were positive for an autologous surface antibody reaction. Five (23%) of 21 were positive for an autologus cytoplasmic antibody, however, 10 (47%) of 21 of the sera gave a positive reaction for cross-reacting cytoplasmic antibodies when tested with a battery of tumor cells obtained from different patients with malignant glial tumors.No reaction was observed with normal brain tissue. Absorption studies indicated the presence of a tumor-associated antigen.This study demonstrated that certain patients with malignant gliomas possess circulating antibodies to cytoplasmic components of their own tumor cells. The fact that a number of sera cross-reacted with tumor cells obtained from different patients suggests that antigenic cross-reactivity exists between malignant glioma cells from different patients. It is suggested that with further refinement, immunofluorescent detection of antibodies could evolve as a useful diagnostic adjunct in malignant glioma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 333792      PMCID: PMC2595517     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  9 in total

1.  AUTOIMMUNE RESPONSE TO MALIGNANT GLIAL TUMORS; PRELIMINARY OBSERVATIONS.

Authors:  M G MITTS; A E WALKER
Journal:  Neurology       Date:  1965-05       Impact factor: 9.910

Review 2.  Immunity to neuroblastomas and melanomas.

Authors:  K E Hellström; I Hellström
Journal:  Annu Rev Med       Date:  1972       Impact factor: 13.739

Review 3.  Blocking antibodies and enhancement.

Authors:  G H Heppner
Journal:  Ser Haematol       Date:  1972

4.  [Immunochemical and immunological study of human brain tumors].

Authors:  B Delpech; A Delpech; J Clément; R Laumonier
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

5.  Autoradiographic and fluorescence antibody studies of the human host immune response to gliomas.

Authors:  A E Eggers
Journal:  Neurology       Date:  1972-03       Impact factor: 9.910

6.  The indentification of foetal antigens in human bone marrow cells.

Authors:  M G Lewis; K M Sheikh; P Avis; V M Whitehead; C Vera
Journal:  Differentiation       Date:  1974-10       Impact factor: 3.880

7.  Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines.

Authors:  G Klein; E Klein; P Clifford
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

Review 8.  Cellular immunity against tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Cancer Res       Date:  1969       Impact factor: 6.242

9.  Human osteosarcomas: immunologic evidence suggesting an associated infectious agent.

Authors:  D L Morton; R A Malmgren
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

  9 in total
  3 in total

Review 1.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

2.  Evaluation of the humoral response of meningioma patients to possible common tumour-associated antigens.

Authors:  S Mottet; A Martin-Achard; N de Tribolet; A C Diserens
Journal:  Acta Neurochir (Wien)       Date:  1980       Impact factor: 2.216

3.  The utilization of native glioma antigens in the assessment of cellular and humoral immune responses in malignant glioma patients.

Authors:  M L Apuzzo; K M Sheikh; M H Weiss; J S Heiden; T Kurze
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.